In the treating postmenopausal osteoporosis.

Amgen announces excellent results for Denosumab postmenopausal osteoporosis trial Amgen has announced results from the pivotal fracture trial evaluating its RANK Ligand inhibitor, denosumab, in the treating postmenopausal osteoporosis. In this pivotal, three-year, international, Phase 3 study of approximately 7,800 women with osteoporosis, patients were randomized to get either denosumab, given by subcutaneous injection once every six months, or placebo shots . For the primary endpoint, treatment with denosumab led to a statistically significant decrease in the incidence of fresh vertebral fractures compared with placebo treatment.


It had been filed with respect to the Marketing campaign for Tobacco-Free Kids, American Cancer Society, American Cancer Society Cancer Action Network, American Heart Association, American Legacy Basis, American Lung Association, American Medical Association, American Public Wellness Association, Kentucky Medical Association, Oncology Nursing Culture and Public Citizen. The groupings are represented by Allison M. Zieve and Gregory A. Beck of General public Citizen, Washington D.C., and Jennifer A. Moore of Grossman and Moore, Louisville, Kentucky. The brief can be found at:.. Amicus brief filed against tobacco companies’ lawsuit challenging FDA tobacco regulation law Today, eleven open public health and consumer advocacy organizations filed a friend of the courtroom brief asking a federal courtroom to reject a lawsuit by R.J.